This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dendreon Announces Presentation Of PROVENGE® (sipuleucel-T) Data At The 2014 Genitourinary Cancer Symposium (ASCO GU)

January 30, 2014 – Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of four PROVENGE ® (sipuleucel-T) abstracts and one abstract for DN24-02, an investigational active cellular immunotherapy, from ongoing clinical trials at the 2014 Genitourinary Cancers Symposium (ASCO GU) from January 30-February 1, 2014 in San Francisco, California.

“The PROVENGE and DN24-02 research presented at this year's ASCO GU Symposium demonstrate Dendreon's ongoing commitment to our immuno-oncology franchise and patients in need of new and innovative treatment options for cancer,” said Andrew S. Sandler, M.D., executive vice president and chief medical officer at Dendreon. “These data further elucidate the mechanism underlying the PROVENGE treatment effect and further our understanding of the role of immunotherapy in cancer treatment.”

The data featuring PROVENGE and DN24-02 studies include:

  • Antigen Spread and Survival with Sipuleucel-T in Patients with Advanced Prostate Cancer (Abstract #88). In the pivotal Phase III IMPACT study, post-hoc subset data demonstrate PROVENGE treatment may result in humoral antigen spread, a process by which the immune response broadens over time to target multiple cancer-related antigens. Additionally, this effect was found to be associated with improved overall survival. These results contribute to an understanding of the mechanism of action for PROVENGE and may enable identification of post-treatment biomarkers of clinical outcome. Poster Session A: Prostate Cancer, Thursday, January 30, 11:30 AM – 1:00 PM PST, Golden Gate Hall Lead Author: Charles G. Drake, M.D., Ph.D., Johns Hopkins University School of Medicine, Baltimore, MD
  • Effect of Prior Abiraterone (ABI) or Enzalutamide (ENZ) on Sipuleucel-T (sip-T) Manufacture in PROCEED Patients (pts) (Abstract #185). A subgroup analysis from the Phase IV PROCEED registry suggests that prior treatment with abiraterone acetate or enzalutamide does not negatively impact PROVENGE manufacturing or product parameters. These results are consistent with prior analyses demonstrating a positive PROVENGE treatment immune effect in patients who have received prior therapies. Poster Session A: Prostate Cancer, Thursday, January 30, 11:30 AM – 1:00 PM PST, Golden Gate Hall Lead Author: Nicholas J. Vogelzang, M.D., Comprehensive Cancer Centers of Nevada, Las Vegas, NV

“Data from the Phase III IMPACT study demonstrate that treatment with sipuleucel-T may result in humoral antigen spread, which was found to be associated with improved overall survival,” said Daniel Petrylak, M.D., professor of medicine, director of Genitourinary Oncology, co-director of Signal Transduction Research Program, Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven. “These results are particularly exciting because they further our understanding of the sipuleucel-T mechanism of action and may enable identification of post-treatment biomarkers of clinical outcome.”

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,107.33 +55.60 0.33%
S&P 500 1,982.20 +8.57 0.43%
NASDAQ 4,452.0790 +27.3750 0.62%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs